COVID Vaccine in India

The coronavirus has made the world go around making people think twice before doing anything, even stepping out for the smallest of things. Countries are trying their best to roll out a vaccine that is efficient enough to save people from contracting the disease and ultimately eradicating it.

The two ahead in the race are Serum Institute of India’s Covishield and Bharat Biotech’s indigenous Covaxin are the two vaccines against Covid-19.

Indian companies are on their toes to make each attempt work, below are some of the important information regarding vaccines in India.

Some of the homegrown vaccines are listed below:

• ZyCov-Di, being developed by Ahmedabad-based Zydus-Cadila

• In Hyderabad, a company by the name of Biological E is the first Indian vaccine by a private organisation in collaboration with Seattle-based HDT Biotech Corporation.

• HGCO19 is India’s first mRNA vaccine formulated by a Pune-based company Genova in collaboration with Seattle-based HDT Biotech Corporation. They have used bits of genetic code to cause an immune response in this vaccine development.

• The Sputnik V vaccine was developed by Dr Reddy’s Lab and Gamaleya National Centre in Russia

• The Serum Institute of India and American vaccine development company Novavax is working together on one of the strong contenders.

Below is the list of the cost of one dose of each vaccine in India:

• Covishield: Rs 200 per dose (for first 100 million doses), Rs 1,000 per dose thereafter at private outlets

• Covaxin: Rs 206 per dose

• Pfizer-BioNTech: Rs 1,431 per dose

• Moderna: Rs 2,348 to Rs 2,715 per dose

• Sinopharm: less than Rs 5,650 per dose

• Sinovac Biotech: Rs 1,027 per dose

• Novavax: Rs 1,114 per dose

• Gamaleya Centre: less than Rs 734 per dose

• Johnson and Johnson: Rs 734 per dose

(With inputs from PTI)

Every countryman is fully engrossed in making the vaccine work with many funding these organisations and many coming forward as volunteers. We will soon overcome this that too full power.

0 0 votes
Article Rating
Facebooktwitterredditpinterestlinkedinmail
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments